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HYPERTENSION
Renal denervation—promising 
data from the DENERHTN trial
Wen-Yi Yang and Jan A. Staessen
Refers to Azizi, M. et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation 
for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet http://dx.doi.org/10.1016/
S0140-6736(14)61942-5
In patients with resistant hypertension, renal denervation plus standardized 
stepped-care antihypertensive treatment (SSAHT) resulted in significant 
blood-pressure lowering compared with SSAHT alone. These new data from 
the DENERHTN trial may indicate that despite the failure of SYMPLICITY 
HTN-3, there is light at the end of the tunnel for renal denervation.
The DENERHTN trial investigators report 
that in patients with resistant hypertension, 
renal denervation together with stand-
ardized step-care antihypertensive treat-
ment (SSAHT) resulted in approximately 
6 mmHg greater reductions in 24 h, daytime 
and night-time systolic blood pressure levels 
at 6 months than did SSAHT alone.1 These 
data are in contrast to the findings of the 
SYMPLICITY HTN-3 trial,2 which failed to 
reach its efficacy end point and showed base-
line-adjusted differences in systolic blood 
pressure between renal denervation and 
sham-operated groups of only 2.4 mmHg 
and 2.0 mmHg on office and 24-h ambula-
tory blood pressure monitoring, respectively. 
The DENERHTN consortium sailed against 
the tide by continuing their trial despite the 
negative findings of SYMPLICITY HTN-3, 
but they have been rewarded by the genera-
tion of novel insights into the effects of renal 
denervation on resistant hypertension.
Design characteristics that differentiate the 
DENERHTH trial from previous studies of 
renal denervation (Table 1)2–5—and increase 
the reliability of the findings—include blinded 
assessment of daytime systolic blood pres-
sure, the primary end point, recruitment and 
monthly follow-up of patients at specialized 
tertiary referral centres, and assessment of 
drug adherence at every clinic visit using the 
eight-item Morisky Medication Adherence 
Scale (MMAS-8) questionnaire. The highly 
standardized drug treatment regimen, which 
reduces confounding by concomitant anti-
hypertensive therapy, is particularly relevant 
for the interpretation of the DENERHTN 
trial results.2 Patients who maintained a 
daytime blood pressure of ≥135 mmHg sys-
tolic or ≥85 mmHg diastolic despite triple 
therapy with indapamide 1.5 mg, ramipril 
10 mg (or irbesartan 300 mg) and amlodi-
pine 5–10 mg daily for 4 weeks (n = 106) were 
randomly assigned to renal denervation and 
control groups.1 From month two to five 
after randomization, if home blood pres-
sure was ≥135 mmHg systolic or ≥85 mmHg 
diastolic, spironolactone 25 mg, bisoprolol 
10 mg, prazosin 5 mg and rilmenidine 1 mg 
per day were sequentially added. Similar pro-
portions of patients in the renal denervation 
and control groups received these add-on 
medications; overall 27.7% of participants 
reached the last step in the treatment algo-
rithm. During follow-up, the median number 
of drugs increased from three to five and the 
proportion of patients with high adherence 
(MMAS-8 score 8) increased from ~63% to 
~73% in both groups.
Notwithstanding the merits of the 
DENERHTN trial, a number of issues limit 
interpretation of the data. The drop-out rates 
in the intention-to-treat and per-protocol 
analyses were higher in the renal denerva-
tion than in the control group (9.4% versus 
0% and 17.0% versus 0%, respectively). 
At the time of randomization, blood pres-
sure was also consistently, albeit not sig-
nificantly, higher in the renal denervation 
group. In the modified intention-to-treat 
analysis, daytime, night-time and 24 h sys-
tolic blood pressures were respectively 
4.5 mmHg (P = 0.15), 5.9 mmHg (P = 0.059) 
and 4.8 mmHg (P = 0.12) higher in the den-
ervation group than in the control group 
(P values calculated using t-tests of data 
reported in Table S1 of the original article1). 
The between-group baseline-adjusted differ-
ences in ambulatory blood pressure, there-
fore, partly depend on the higher baseline 
blood pressure levels in the denervation 
group; there was no significant difference in 
blood pressure levels at 6 months in the study 
groups (P ≥0.45). According to the regression 
model derived in the per-protocol analysis, a 
4.5 mmHg higher daytime systolic pressure 
by itself accounts for a ~2 mmHg lower blood 
pressure at 6 months. The between-group 
Table 1 | Randomized clinical trials of renal denervation in patients with resistant hypertension
Characteristic DENERHTN1 OSLO RDN4 PRAGUE-155 SYMPLICITY 
HTN-23
SYMPLICITY 
HTN-32
Number of patients
Control/renal 
denervation (analysed)
53/53 
(53/48)
10/10 
(10/9)
54/52 
(54/52)
52/54 
(51/49)
171/364 
(171/353)
Blood pressure criteria (mmHg)
Office systolic/diastolic ≥140/≥90 >140/NS >140/NS ≥160/NS >160/NS
Ambulatory systolic/
diastolic (period) 
≥135/≥85 
(Daytime)
>135/NA 
(Daytime)
>130/NA 
(24 h)
NS/NS 
(NS)
≥135/NA 
(24 h)
Systolic blood pressure (mmHg)
Office (control/renal denervation)
Baseline
Change at 6 months
156/160 
–9.5/–15.1 
160/156
2/–8
155/159 
–14.3/–12.4 
178/178
1/–32 
180/180 
–11.7/–14.1 
24 h (control/renal denervation)
Baseline 
Change at 6 months
147/152
–9.5/–15.4 
152/152
21/–10 
147/149 
–8.1/–8.6 
NS/NS
–3/–11 
160/159 
–4.8/–6.7 
Abbreviation: NA, not applicable; NS, not specified.
© 2015 Macmillan Publishers Limited. All rights reserved
MAY 2015 | VOLUME 11 www.nature.com/nrneph
NEWS & VIEWS
difference in entry blood pressure levels 
might be the result of  randomization of three 
or fewer patients at 10 of 15 centres.
A consensus exists in the literature that 
blood-pressure lowering effects assessed by 
home or daytime ambulatory monitoring are 
generally 30–40% lower than those observed 
on office measurement.6 By contrast, the 
DENERHTN investigators observed within-
group changes in systolic blood pressures 
of similar magnitudes on office, home 
and daytime ambulatory measurement.1 
Titration of add-on medication based on 
self-measured home blood pressures might 
explain this finding. However, in 203 patients 
randomly assigned to treatment adjust-
ment guided by home blood pressure in the 
THOP trial,6 in which the treatment regimen 
was as thoroughly standardized as in the 
DENERHTN trial, decreases in systolic 
pressure were larger on office than on out-
of-office assessment, averaging 15.3 mmHg, 
11.1 mmHg and 11.3 mmHg on office, home 
and daytime measurement, respectively. 
Alternative explanations for the similar treat-
ment effects on systolic blood pressure across 
measurement platforms in the DENERHTN 
trial include assessment of office blood pres-
sure in the morning before intake of medi-
cations and, at variance with other trials in 
the field,2-5 the use of both systolic and dia-
stolic blood pressure as entry criteria and 
treatment goals. Patients with white-coat or 
masked systolic hypertension might have 
entered the trial based on a qualifying dia-
stolic blood pressure on daytime ambulatory 
or office measurement, respectively.
A remarkable design feature of the 
DENERHTN trial is the stepwise add-on 
treatment with sympatholytic drugs. This 
protocol was probably based on the premise 
that these drugs would enhance the effects 
of renal denervation, which was apparently 
correct.1 The increasing adherence to multi-
ple drug treatment during the follow-up 
period might reflect a learning curve in com-
pleting the MMAS-8 questionnaire or exem-
plify the Hawthorne effect, by which patients 
improve their behaviour in response to their 
awareness of being observed.7 Measurement 
of drug concentrations in urine would be 
required to investigate these possibilities.
The data generated by the DENERHTN 
trial will substantially change the field of 
renal denervation as a treatment modality 
for hypertension. First, all renal denerva-
tion trials conducted to date1-5 have used the 
single-electrode radiofrequency Symplicity™ 
catheter (Medtronic, USA). The modest 
blood pressure reduction observed in the 
DENERHTN trial confirmed that this device 
is too imprecise and operator dependent to 
meet the objective of effective renal sym-
pathetic denervation. Ultrasound-based 
catheters and multi-electrode catheters with 
intelligent designs that include inflatable 
balloons or expandable baskets for stabili-
zation may have greater efficacy than the 
Symplicity™ denervation system. Moreover, 
in contrast to radiofrequency ablation, cir-
cumferential delivery of ultrasound energy 
at an adjustable depth in the renal arterial 
adventitia does not damage the endothelium.
Second, resistant hypertension is cur-
rently defined as office blood pressure of 
≥140 mmHg systolic or ≥90 mmHg diastolic 
despite treatment with three classes of anti-
hypertensive drugs, including a diuretic, at 
maximal doses. The DENERHTN trial, in 
which patients needed a median of five drugs 
for blood pressure control, with or without 
renal denervation, proves that the current 
indication for the procedure is a misconcep-
tion. In line with the pathophysiological evi-
dence,8 signs of sympathetic dysregulation in 
the presence of hypertension—preferably 
in untreated patients—might become the 
prime indication for renal denervation rather 
than the number of antihypertensive drugs.
Renal nerve stimulation can be used to 
identify the anatomical sites where lesions 
should be delivered and to ascertain the 
completeness of denervation, thereby 
addressing the huge variability in the course 
of the renal sympathetic nerves along the 
renal arteries.9 Accessory renal arteries 
that cannot be engaged for denervation 
represent an anatomical constraint that 
has not been accounted for in most trials 
conducted to date. Short-term (6 month) 
blood pressure results or grossly incom-
plete follow-up10 cannot be translated into 
durability of the blood- pressure response or 
the prevention of cardiovascular complica-
tions. The DENERHTN investigators will 
likely soon report whether or not the need 
to continue or intensify antihypertensive 
treatment after renal denervation limits 
the cost-effectivenes s of the procedure in 
t reatment-resistant hypertension.1
After years of market-driven research, 
the DENERHTN trial1 has generated novel 
insights that suggest that there is light at the 
end of the tunnel for renal denervation. The 
experts who have led the trials conducted to 
date agree that a minority of highly selected 
patients experience a substantial blood- 
pressure response to the procedure. Full 
access to the available data should enable a 
patient-level meta-analysis to characterize 
this small subgroup of responders, thereby 
informing future trials, preferably in never-
treated patients with hypertension and 
e vidence of sympathetic overactivity.8
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